1,000 filings
Page 4 of 50
424B5
ccycxi nzski
30 Nov 23
Prospectus supplement for primary offering
4:58pm
424B5
9f5cz ij68h
28 Nov 23
Prospectus supplement for primary offering
4:06pm
424B3
jwky8ei25oqtteg
28 Nov 23
Prospectus supplement
4:03pm
8-K
bnzov
28 Nov 23
Material Modifications to Rights of Security Holders
9:00am
8-K
vdk5xqlfcn1k wdq33s
24 Nov 23
Seelos Therapeutics Announces 1-for-30 Reverse Stock Split
12:07pm
8-K
imkq6ln qydljpw
24 Nov 23
Seelos Therapeutics Announces 1-for-30 Reverse Stock Split
11:10am
8-K
prxcdyiw1
3 Nov 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:15pm
8-K
t0rori16yv17 br7pf
2 Oct 23
Entry into a Material Definitive Agreement
6:03am
EFFECT
pex2ip74w
2 Oct 23
Notice of effectiveness
12:15am
424B3
61pyfyb8qgr dm
29 Sep 23
Prospectus supplement
4:56pm
CORRESP
5h8nm
26 Sep 23
Correspondence with SEC
12:00am
8-K
al0iad2bnixvco9ry0f
25 Sep 23
Entry into a Material Definitive Agreement
4:06pm
424B5
aaddktgjnx
25 Sep 23
Prospectus supplement for primary offering
6:02am
8-K
af9wq0 nvlh67fbhz
20 Sep 23
Seelos Therapeutics Announces Top Line Results from SLS-002 Phase II Study in Adults with Major Depressive Disorder at Imminent Risk of Suicide
7:00am
UPLOAD
5cpqiwnt evfau
20 Sep 23
Letter from SEC
12:00am
8-K
p4kursej9wmoptkfj
14 Sep 23
Other Events
9:00am
4
hki09xeu8lp
1 Sep 23
SEELOS THERAPEUTICS / Michael Joseph Golembiewski ownership change
4:15pm